* NCBI Logo * Resources o All Resources o Chemicals & Bioassays <#chemicals-bioassays> + BioSystems + PubChem BioAssay + PubChem Compound + PubChem Structure Search + PubChem Substance + All Chemicals & Bioassays Resources... o DNA & RNA <#dna-rna> + BLAST (Basic Local Alignment Search Tool) + BLAST (Stand-alone) + E-Utilities + GenBank + GenBank: BankIt + GenBank: Sequin + GenBank: tbl2asn + Genome Workbench + Influenza Virus + Nucleotide Database + PopSet + Primer-BLAST + ProSplign + Reference Sequence (RefSeq) + RefSeqGene + Sequence Read Archive (SRA) + Splign + Trace Archive + UniGene + UniSTS + All DNA & RNA Resources... o Data & Software <#data-software> + BLAST (Basic Local Alignment Search Tool) + BLAST (Stand-alone) + Cn3D + Conserved Domain Search Service (CD Search) + E-Utilities + GenBank: BankIt + GenBank: Sequin + GenBank: tbl2asn + Genome ProtMap + Genome Workbench + Primer-BLAST + ProSplign + PubChem Structure Search + SNP Submission Tool + Splign + Vector Alignment Search Tool (VAST) + All Data & Software Resources... o Domains & Structures <#domains-structures> + BioSystems + Cn3D + Conserved Domain Database (CDD) + Conserved Domain Search Service (CD Search) + Structure (Molecular Modeling Database) + Vector Alignment Search Tool (VAST) + All Domains & Structures Resources... o Genes & Expression <#genes-expression> + BioSystems + Database of Genotypes and Phenotypes (dbGaP) + E-Utilities + Gene + Gene Expression Omnibus (GEO) Database + Gene Expression Omnibus (GEO) Datasets + Gene Expression Omnibus (GEO) Profiles + Genome Workbench + HomoloGene + Map Viewer + Online Mendelian Inheritance in Man (OMIM) + RefSeqGene + UniGene + All Genes & Expression Resources... o Genetics & Medicine <#genetics-medicine> + Bookshelf + Database of Genotypes and Phenotypes (dbGaP) + Genetic Testing Registry + Influenza Virus + Map Viewer + Online Mendelian Inheritance in Man (OMIM) + PubMed + PubMed Central (PMC) + PubMed Clinical Queries + RefSeqGene + All Genetics & Medicine Resources... o Genomes & Maps <#genomes-maps> + Database of Genomic Structural Variation (dbVar) + GenBank: tbl2asn + Genome + Genome Project + Genome ProtMap + Genome Workbench + Influenza Virus + Map Viewer + Nucleotide Database + PopSet + ProSplign + Sequence Read Archive (SRA) + Splign + Trace Archive + UniSTS + All Genomes & Maps Resources... o Homology <#homology> + BLAST (Basic Local Alignment Search Tool) + BLAST (Stand-alone) + BLAST Link (BLink) + Conserved Domain Database (CDD) + Conserved Domain Search Service (CD Search) + Genome ProtMap + HomoloGene + Protein Clusters + All Homology Resources... o Literature <#literature> + Bookshelf + E-Utilities + Journals in NCBI Databases + MeSH Database + NCBI Handbook + NCBI Help Manual + NCBI News + PubMed + PubMed Central (PMC) + PubMed Clinical Queries + All Literature Resources... o Proteins <#proteins> + BioSystems + BLAST (Basic Local Alignment Search Tool) + BLAST (Stand-alone) + BLAST Link (BLink) + Conserved Domain Database (CDD) + Conserved Domain Search Service (CD Search) + E-Utilities + ProSplign + Protein Clusters + Protein Database + Reference Sequence (RefSeq) + All Proteins Resources... o Sequence Analysis <#sequence-analysis> + BLAST (Basic Local Alignment Search Tool) + BLAST (Stand-alone) + BLAST Link (BLink) + Conserved Domain Search Service (CD Search) + Genome ProtMap + Genome Workbench + Influenza Virus + Primer-BLAST + ProSplign + Splign + All Sequence Analysis Resources... o Taxonomy <#taxonomy> + Taxonomy + Taxonomy Browser + Taxonomy Common Tree + All Taxonomy Resources... o Training & Tutorials <#training-tutorials> + NCBI Education Page + NCBI Handbook + NCBI Help Manual + NCBI News + Science Primer + All Training & Tutorials Resources... o Variation <#variation> + Database of Genomic Structural Variation (dbVar) + Database of Genotypes and Phenotypes (dbGaP) + Database of Single Nucleotide Polymorphisms (dbSNP) + SNP Submission Tool + All Variation Resources... * How To o All How To o Chemicals & Bioassays o DNA & RNA o Data & Software o Domains & Structures o Genes & Expression o Genetics & Medicine o Genomes & Maps o Homology o Literature o Proteins o Sequence Analysis o Taxonomy o Training & Tutorials o Variation * Skip to main content <#maincontent> * Skip to navigation <#navcontent> * About NCBI Accesskeys My NCBI Sign In Sign Out PubMed US National Library of Medicine National Institutes of Health Search termSearch database Clear input <#> Search * Limits * Advanced * Help Display Settings: <#> * Abstract <#> Format * Summary * Summary (text) * Abstract * Abstract (text) * MEDLINE * XML * PMID List Apply Send to: <#> Choose Destination * File * Clipboard * Collections * E-mail * Order * My Bibliography * Citation manager * Format Create File * 1 selected item: 18602688 * FormatMeSH and Other Data * E-mail * Subject * Additional text E-mail "SPAM" filtering software notice Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File Lancet. <#> 2008 Jul 12;372(9633):145-54. Epub 2008 Jul 3. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Wood C , Srivastava P , Bukowski R , Lacombe L , Gorelov AI , Gorelov S , Mulders P , Zielinski H , Hoos A , Teofilovici F , Isakov L , Flanigan R , Figlin R , Gupta R , Escudier B ; C-100-12 RCC Study Group . Collaborators (111)<#> Madersbacher S , Marberger M , Richard V , Billiet I , Andrianne R , Focan C , Vermorken J , Chin J , Tanguay S , Klotz L , Gleave M , Jewett M , Lacombe L , Steinhoff G , Barr R , Escudier B , Linassier C , Delva R , Jacqmin D , Caty A , Négrier S , Geoffrois L , Gravis G , Peschel CI , Grünwald V , Jakse G , Wirth M , Dietel A , Lindner A , Nativ O , Gofrit O , Sidi A , Fosså S , Narula R , Borkowski A , Krajka K , Bar K , Sikorski A , Chlosta P , Wyczolkowski M , Borowka A , Darewicz B , Zielinski H , Dobrovolskaya NY , Gorelov AI , Mikhailov S , Karlov P , Al-Shukri S , Moiseyenko V , Gorelov S , González-Larriba JL , Jiménez-Cruz F , Briones JR , Garcia D , Villavicencio H , Wullt B , Johansson E , Norlen BJ , Lundstam S , Ljungberg B , Sulser T , Mulders PF , Oliver T , Newman H , Hegde U , Reed D , Amato R , Poll W , Shalhav AL , Wood C , Soloway M , Crawford D , Ratner M , Sahasrabudhe D , Grob BM , Rodriguez R , Kabbinavar F , See W , Andriole G , Bergreen P , Flanigan R , Weiser A , Fishman M , Kuzel T , Babayan R , Campbell S , Schwartzberg L , O'Donnell M , Rowland R , Thompson J , Plante M , Ebbinghaus S , Richart J , Rosenberg J , Urba W , Blute M , Tomera K , Clark P , Reddy S , Klein F , Smith A , Thrasher JB , Bilhartz D , Gomella L , Vestal JC , Quinn D , Monnig WB , Pattaras J , Teigland CM , Steckel J , Sosman J . Source M D Anderson Cancer Center, Houston, TX, USA. cgwood@mdanderson.org Abstract BACKGROUND: Treatment of localised renal cell carcinoma consists of partial or radical nephrectomy. A substantial proportion of patients are at risk for recurrence because no effective adjuvant therapy exists. We investigated the use of an autologous, tumour-derived heat-shock protein (glycoprotein 96)-peptide complex (HSPPC-96; vitespen) as adjuvant treatment in patients at high risk of recurrence after resection of locally advanced renal cell carcinoma. METHODS: In this open-label trial, patients were randomly assigned to receive either vitespen (n=409) or observation alone (n=409) after nephrectomy. Randomisation was done in a one to one ratio by a computer-generated pseudo-random number generator, with a block size of four, and was stratified by performance score, lymph node status, and nuclear grade. Vitespen was given intradermally once a week for 4 weeks, then every 2 weeks until vaccine depletion. The primary endpoint was recurrence-free survival. The final analysis of recurrence-free survival was planned to take place after 214 or more events of disease recurrence or deaths before recurrence had occurred. Analysis was by intention to treat (ITT). This study is registered with ClinicalTrials.gov, number NCT00033904. FINDINGS: 48 patients in the vitespen group and 42 in the observation group were excluded from the ITT population because they did not meet post-surgery inclusion criteria; the ITT population thus consisted of 361 patients in the vitespen group and 367 in the observation group. Final analysis of recurrence-free survival was triggered in November, 2005. Re-review of all patients in the ITT population by the clinical events committee identified 149 actual recurrences (73 in the vitespen group and 76 in the observation group), nine deaths before recurrence (two in the vitespen group and seven in the observation group), and 124 patients with baseline metastatic or residual disease (61 in the vitespen group and 63 in the observation group). Thus, after a median follow-up of 1.9 years (IQR 0.9-2.5) in the ITT population, recurrence events were reported in 136 (37.7%) patients in the vitespen group and 146 (39.8%) in the observation group (hazard ratio 0.923, 95% CI 0.729-1.169; p=0.506). After continued follow-up until March, 2007, there had been 70 deaths in the vitespen group and 72 in the observation group (p=0.896); however, overall survival data were not mature, and patients continue to be followed up for survival. In predefined exploratory analyses by AJCC stage, recurrence events in patients with stage I or II disease were reported in 19 (15.2%) patients in the vitespen group and 31 (27.0%) in the observation group (hazard ratio 0.576, 95% CI 0.324-1.023; p=0.056). The most commonly reported adverse events in the vitespen group were injection-site erythema (n=158) and injection-site induration (n=153). One serious adverse event-autoimmune thyroiditis of grade 2 severity-was reported in the vitespen group; no treatment-related grade 3 or 4 adverse events were reported. INTERPRETATION: No difference in recurrence-free survival was seen between patients given vitespen and those who received no treatment after nephrectomy for renal cell carcinoma. A possible improvement in recurrence-free survival in patients with early stage disease who received vitespen will require further validation. Comment in * Lancet. 2008 Jul 12;372(9633):92-3. * Nat Clin Pract Urol. 2008 Dec;5(12):644-5. PMID: 18602688 [PubMed - indexed for MEDLINE] Publication Types, MeSH Terms, Substances, Secondary Source ID<#> Publication Types * Clinical Trial, Phase III <#> * Multicenter Study <#> * Randomized Controlled Trial <#> * Research Support, Non-U.S. Gov't <#> MeSH Terms * Adult <#> * Aged <#> * Aged, 80 and over <#> * Cancer Vaccines/adverse effects <#> * Cancer Vaccines/therapeutic use* <#> * Disease-Free Survival <#> * Female <#> * Heat-Shock Proteins/adverse effects <#> * Heat-Shock Proteins/therapeutic use* <#> * Humans <#> * Kidney Neoplasms/pathology <#> * Kidney Neoplasms/prevention & control* <#> * Kidney Neoplasms/surgery <#> * Male <#> * Middle Aged <#> * Neoplasm Recurrence, Local/prevention & control* <#> * Observation <#> * Postoperative Period <#> * Risk Factors <#> Substances * Cancer Vaccines <#> * Heat-Shock Proteins <#> * vitespin <#> Secondary Source ID * ClinicalTrials.gov/NCT00033904 <#> LinkOut - more resources<#> Full Text Sources * Elsevier Science * EBSCO * OhioLINK Electronic Journal Center * ProQuest Information and Learning * Swets Information Services Other Literature Sources * COS Scholar Universe * Labome Researcher Resource - ExactAntigen/Labome Medical * ClinicalTrials.gov * Kidney Cancer - MedlinePlus Health Information * Supplemental Content Click here to read Save items <#> Favorite <#>View more options <#> * Create collection... <#> * Manage collections... loading Related citations in PubMed <#> * Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. [Lancet. 2004] Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. /Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, et al. //Lancet. 2004 Feb 21; 363(9409):594-9. / * Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. [Lancet. 2008] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. /Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, et al. //Lancet. 2008 Jul 12; 372(9633):117-26. / * Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. [Lancet. 2008] Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. /Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al. //Lancet. 2008 Aug 9; 372(9637):449-56. Epub 2008 Jul 22./ * Review Vaccine therapy in patients with renal cell carcinoma. [Eur Urol. 2009] Review Vaccine therapy in patients with renal cell carcinoma. /Van Poppel H, Joniau S, Van Gool SW. //Eur Urol. 2009 Jun; 55(6):1333-42. Epub 2009 Jan 30./ * Review Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium. [Drugs R D. 2007] Review Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium. /. //Drugs R D. 2007; 8(5):321-34. / See reviews... See all... Cited by 12 PubMed Central articles <#> * Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies. [J Transl Med. 2011] Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies. /Tischer S, Basila M, Maecker-Kolhoff B, Immenschuh S, Oelke M, Blasczyk R, Eiz-Vesper B. //J Transl Med. 2011 Oct 12; 9:175. Epub 2011 Oct 12./ * Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. [J Exp Clin Cancer Res. 2011] Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. /Guo QY, Yuan M, Peng J, Cui XM, Song G, Sui X, Lu SB. //J Exp Clin Cancer Res. 2011 Feb 26; 30:24. Epub 2011 Feb 26./ * Hsp110-mediated enhancement of CD4+ T cell responses to the envelope glycoprotein of members of the family Flaviviridae in vitro does not occur in vivo. [Clin Vaccine Immunol. 2011] Hsp110-mediated enhancement of CD4+ T cell responses to the envelope glycoprotein of members of the family Flaviviridae in vitro does not occur in vivo. /McLaughlin K, Carr VB, Iqbal M, Seago J, Lefevre EA, Robinson L, Prentice H, Charleston B. //Clin Vaccine Immunol. 2011 Feb; 18(2):311-7. Epub 2010 Dec 8./ See all... Related information <#> * Related Citations Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first. * Substance (MeSH Keyword) PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles. * Cited in PMC Full-text articles in the PubMed Central Database that cite the current articles. Recent activity <#> Clear Turn Off Turn On * An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observati... An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008 Jul 12 ;372(9633):145-54. Epub 2008 Jul 3 . PubMed Your browsing activity is empty. Activity recording is turned off. Turn recording back on See more... You are here: NCBI > Literature > PubMed Write to the Help Desk Simple NCBI Directory * Getting Started * NCBI Education * NCBI Help Manual * NCBI Handbook * Training & Tutorials * Resources * Chemicals & Bioassays * Data & Software * DNA & RNA * Domains & Structures * Genes & Expression * Genetics & Medicine * Genomes & Maps * Homology * Literature * Proteins * Sequence Analysis * Taxonomy * Training & Tutorials * Variation * Popular * PubMed * Nucleotide * BLAST * PubMed Central * Gene * Bookshelf * Protein * OMIM * Genome * SNP * Structure * Featured * Genetic Testing Registry * PubMed Health * GenBank * Reference Sequences * Map Viewer * Human Genome * Mouse Genome * Influenza Virus * Primer-BLAST * Sequence Read Archive * NCBI Information * About NCBI * Research at NCBI * NCBI Newsletter * NCBI FTP Site * NCBI on Facebook * NCBI on Twitter * NCBI on YouTube External link. Please review our privacy policy . NLM NIH DHHS USA.gov Copyright | Disclaimer | Privacy | Accessibility | Contact National Center for Biotechnology Information , U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA Preferences <#>Turn off <#> External link. Please review our privacy policy . *